Bird Flu > Bird Flu News > Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010
Ardea Biosciences, Inc. a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), today reported recent accomplishments and financial results for the first quarter ended March 31, 2010.